When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.
But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.
What is the story behind this new drug?
Guest: Pam Belluck, a health and ... Show More
Today
Trump 2.0: The President’s Affordability Problem
President Trump was elected in 2024 on the promise that he would fix the economy. Now, a new poll from The New York Times/Siena reveals that the issue may be driving voters away.Nate Cohn, the chief political analyst at The Times, explains what the poll tells us.Guest: Nate Cohn, ... Show More
32m 44s
Nov 2021
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ... Show More
9m 45s